利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

87 条记录 (耗时 0.038 秒)

    Methods and compositions for treating cancer
    33.
    发明授权
    Methods and compositions for treating cancer 有权
    治疗癌症的方法和组合物

    公开(公告)号：US09249466B2

    公开(公告)日：2016-02-02

    申请号：US13520472

    申请日：2011-01-10

    申请人： Qiang Yu ,  Jing Tan

    发明人： Qiang Yu ,  Jing Tan

    IPC分类号： C12N15/11 ,  C12Q1/68 ,  A61K45/06 ,  G01N33/574 ,  A61K31/436 ,  A61K31/506 ,  A61K31/713 ,  C12Q1/42 ,  G01N33/68

    CPC分类号： C12Q1/6886 ,  A61K31/436 ,  A61K31/506 ,  A61K31/713 ,  A61K45/06 ,  C12Q1/42 ,  G01N33/57407 ,  G01N33/6893

    摘要： We describe a method of determining whether a cancer cell is likely to be resistant to treatment by an mTOR inhibitor. The method may comprise detecting PPP2R2B (GenBank Accession Number: NM_18167) in or of the cell. It may, alternatively, or in addition, comprise detecting PDK1 (GenBank Accession Number: NM_002613), in or of the cell. The method may comprise detecting methylation of the PPP2R2B promoter in or of the cell. It may comprise detecting the expression and/or activity of PPP2R2B in or of the cell. It may comprise detecting PDK1 mediated Myc phosphorylation activity. Methods of choosing a treatment for an individual suffering from or suspected to be suffering from a cancer, determining whether an individual suffering from or suspected to be suffering from a cancer will respond to treatment by an mTOR inhibitor, increasing the sensitivity of a cancer cell to treatment by an mTOR inhibitor, for treating or preventing cancer in an individual suffering or suspected to be suffering from cancer are also provided. We further provide for a combination of an inhibitor of PDK1 expression and/or activity and an mTOR inhibitor for use in a method of treatment or prevention of cancer.

    摘要翻译： 我们描述一种确定癌细胞是否可能对mTOR抑制剂治疗有抗性的方法。 该方法可以包括在细胞内或细胞中检测PPP2R2B（GenBank登录号：NM_18167）。 或者或另外还包括检测细胞内或细胞中的PDK1（GenBank登录号：NM_002613）。 该方法可以包括检测细胞内或细胞中的PPP2R2B启动子的甲基化。 它可以包括检测细胞中或细胞中的PPP2R2B的表达和/或活性。 它可以包括检测PDK1介导的Myc磷酸化活性。 为患有或怀疑患有癌症的个体选择治疗方法，确定患有或怀疑患有癌症的个体是否会对mTOR抑制剂的治疗产生反应，从而增加癌细胞的敏感性 还提供了用于治疗或预防患有或怀疑患有癌症的个体的癌症的mTOR抑制剂的治疗。 我们进一步提供PDK1表达和/或活性的抑制剂和用于治疗或预防癌症的方法中的mTOR抑制剂的组合。

    Employing spillover tables for data updates
    34.
    发明授权
    Employing spillover tables for data updates 有权
    使用溢出表进行数据更新

    公开(公告)号：US08706619B1

    公开(公告)日：2014-04-22

    申请号：US12823733

    申请日：2010-06-25

    申请人： Qiang Yu ,  David C. Jernberg ,  Joseph E. Magerramov

    发明人： Qiang Yu ,  David C. Jernberg ,  Joseph E. Magerramov

    IPC分类号： G06Q40/00 ,  G06Q10/06 ,  G06Q20/10 ,  G06F17/30 ,  G06F9/46

    CPC分类号： G06Q40/12 ,  G06F9/466 ,  G06F9/526 ,  G06F17/30171 ,  G06F17/30362 ,  G06Q10/06 ,  G06Q20/10 ,  G06Q20/405 ,  G06Q40/00 ,  G06Q40/02

    摘要： Disclosed are various embodiments for employing spillover tables to improve performance of data store updates. A request to update a data field is received, and if an exclusive lock on a data table cannot be obtained, the request is placed in a spillover table until the exclusive lock can be obtained. If the request causes a constraint on the data field to be violated or causes the data field to move closer to the constraint, the request is not placed in the spillover table. A spillover task can collapse entries in the spillover table into the data store when an exclusive lock can be obtained.

    摘要翻译： 披露了采用溢出表来提高数据存储更新性能的各种实施例。 接收到更新数据字段的请求，如果不能获得对数据表的排他锁，则请求将被放置在溢出表中，直到可以获得排他锁。 如果请求导致对数据字段的约束被违反或导致数据字段更接近约束，则请求不会放置在溢出表中。 当可以获得排他锁时，溢出任务可以将溢出表中的条目折叠到数据存储中。

    Composite light weight gypsum wallboard
    36.
    再颁专利
    Composite light weight gypsum wallboard 有权
    复合轻质石膏墙板

    公开(公告)号：USRE44070E1

    公开(公告)日：2013-03-12

    申请号：US13525252

    申请日：2012-06-15

    申请人： Qiang Yu ,  Weixin D. Song

    发明人： Qiang Yu ,  Weixin D. Song

    IPC分类号： B32B3/26 ,  B32B13/00 ,  C04B28/14

    CPC分类号： C04B28/14 ,  C04B2111/0062 ,  Y02W30/97 ,  Y10T428/24479 ,  C04B14/42 ,  C04B18/24 ,  C04B22/16 ,  C04B24/226 ,  C04B24/383 ,  C04B2103/408

    摘要： The invention provides a light weight composite gypsum board including a foamed low density set gypsum core, a top non-foamed (or reduced-foamed) bonding high density layer and a bottom non-foamed (or reduced-foamed) bonding high density layer, a top cover sheet bonded to the foamed low density set gypsum core by the top non-foamed (or reduced-foamed) bonding high density layer, and a bottom cover sheet bonded to the foamed low density set gypsum core by the bottom non-foamed (or reduced-foamed) bonding high density layer. The foamed low density set gypsum core is prepared having a density of less than about 30 pcf using soap foam in the gypsum-containing slurry. The combination of components provide a composite gypsum board having light weight and high strength.

    摘要翻译： 本发明提供了一种重量轻的复合石膏板，其包括发泡低密度石膏芯，顶部非发泡（或还原发泡）键合高密度层和底部非发泡（或还原发泡）键合高密度层， 通过顶部非发泡（或还原发泡）键合高密度层与发泡的低密度凝固石膏芯结合的顶盖片，以及通过底部未发泡的，与发泡的低密度凝固石膏芯接合的底盖片 （或还原发泡）键合高密度层。 使用含石膏浆料中的肥皂泡沫，制备密度低于约30PCF的泡沫低密度凝固石膏芯。 组分的组合提供了重量轻且强度高的复合石膏板。

    Methods for cancer therapy and stem cell modulation
    37.
    发明授权
    Methods for cancer therapy and stem cell modulation 有权
    癌症治疗和干细胞调节方法

    公开(公告)号：US08058258B2

    公开(公告)日：2011-11-15

    申请号：US12281470

    申请日：2006-11-15

    申请人： Qiang Yu ,  Jing Tan ,  Xiao Jing Yang

    发明人： Qiang Yu ,  Jing Tan ,  Xiao Jing Yang

    IPC分类号： A01N43/04 ,  A61K31/70

    CPC分类号： A61K31/519 ,  A61K31/52

    摘要： The present invention relates to a method of inducing apoptosis in a tumour cell as well as modulating pluripotency and/or self-renewing characteristics of a stem/progenitor cell. The method comprises administering to the respective cell a compound of general formula (I). In general formula A is C or N. R1, R4 and R5 are, independently selected, H or aliphatic, cycloaliphatic aromatic, arylaliphatic, or arylcycloaliphatic hydrocarbyl groups, that comprise 0-3 heteroatoms being N, O, S, or Si. R4 and R5 may optionally be linked so as to define an aliphatic hydrocarbyl bridge. R2 is H or a halogen, such as F or Cl. R3 is H, or an aliphatic or arylaliphatic hydrocarbyl group comprising 1-8 main chain carbon atoms and 0-3 heteroatoms being N, O, S, Si, or a halogen such as Cl or F. Also provided is a pharmaceutical composition for inducing apoptosis in a tumour cell and/or modulating pluripotency and/or self-renewing characteristics of a stem/progenitor cell. The pharmaceutical composition comprises a compound as defined above or a pharmaceutically acceptable salt thereof and a carrier or diluent.

    摘要翻译： 本发明涉及诱导肿瘤细胞凋亡的方法以及调节干细胞/祖细胞的多能性和/或自我更新特性。 该方法包括向各细胞施用通式（I）的化合物。 通式A是C或N.R 1，R 4和R 5独立地选自H或脂族，脂环族芳族，芳基脂族或芳基环脂族烃基，其包含0-3个杂原子是N，O，S或Si。 R 4和R 5可以任选连接以限定脂族烃基桥。 R2是H或卤素，例如F或Cl。 R 3是H，或包含1-8个主链碳原子和0-3个杂原子的脂族或芳基脂族烃基是N，O，S，Si或卤素如Cl或F.还提供了用于诱导 肿瘤细胞凋亡和/或调节干细胞/祖细胞的多能性和/或自我更新特性。 药物组合物包含如上所定义的化合物或其药学上可接受的盐和载体或稀释剂。